The patent for the original Semaglutide drug (Ozempic) is set to expire on March 20, which will lead to a flood of nearly 50 cheaper generic versions in the Indian market. This will significantly increase accessibility and affordability for patients. In response, CDSCO has mandated that manufacturers and importers submit a comprehensive "risk management plan." This plan is essential for continuous post-market monitoring of the drug's safety profile, identifying adverse effects, and implementing measures to minimize risks, especially with the influx of many new generic manufacturers.

Semaglutide is a GLP-1 receptor agonist. It mimics the natural hormone GLP-1, which has multiple effects. In practice, a patient taking Semaglutide might find they eat smaller portions, feel satisfied with less food, and snack less frequently throughout the day, leading to a sustained reduction in calorie intake and, consequently, weight loss, alongside better blood sugar control.

• •It increases insulin release when blood sugar is high, helping to lower glucose levels.
• •It decreases glucagon, a hormone that raises blood sugar, further aiding glucose control.
• •Crucially, it slows down the rate at which food leaves the stomach, making you feel full for longer.
• •It also signals fullness to the brain, reducing appetite and cravings.

This is a critical public health and policy challenge.

• •Increasing Accessibility: The influx of cheaper generics is vital for making Semaglutide affordable and available to a larger population suffering from Type 2 diabetes and obesity, which are growing health burdens in India. This aligns with the goal of universal healthcare access.
• •Preventing Misuse: However, Semaglutide is a prescription-only drug with potential side effects. Unmonitored use for purely cosmetic weight loss, without medical supervision, could lead to adverse health outcomes. The government must ensure its 'prescription-only' status is strictly enforced.
• •Balancing Act: The government should strengthen CDSCO's regulatory oversight, particularly for the quality and safety of generic versions. Simultaneously, public awareness campaigns should educate citizens about the drug's proper use, potential risks, and the importance of medical consultation, rather than relying on celebrity endorsements or social media trends. Robust pharmacovigilance (monitoring drug safety post-market) will also be crucial.

The sale, promotion, and regulation of Semaglutide in India are primarily governed by the Drugs and Cosmetics Act, 1940, and its associated rules. The apex regulatory body responsible for its enforcement is the Central Drugs Standard Control Organisation (CDSCO). Recently, in March 2026, CDSCO issued a public advisory mandating that Semaglutide and other GLP-1 agonist drugs must be sold only on the prescription of a registered medical practitioner. Furthermore, it explicitly prohibited all manufacturers, importers, and market authorization holders from engaging in any promotional activities, including 'disease awareness campaigns' or 'influencer engagement,' that create brand recall or product visibility for prescription-only drugs.

The patent for the original Semaglutide drug (Ozempic) is set to expire on March 20, which will lead to a flood of nearly 50 cheaper generic versions in the Indian market. This will significantly increase accessibility and affordability for patients. In response, CDSCO has mandated that manufacturers and importers submit a comprehensive "risk management plan." This plan is essential for continuous post-market monitoring of the drug's safety profile, identifying adverse effects, and implementing measures to minimize risks, especially with the influx of many new generic manufacturers.

Semaglutide is a GLP-1 receptor agonist. It mimics the natural hormone GLP-1, which has multiple effects. In practice, a patient taking Semaglutide might find they eat smaller portions, feel satisfied with less food, and snack less frequently throughout the day, leading to a sustained reduction in calorie intake and, consequently, weight loss, alongside better blood sugar control.

• •It increases insulin release when blood sugar is high, helping to lower glucose levels.
• •It decreases glucagon, a hormone that raises blood sugar, further aiding glucose control.
• •Crucially, it slows down the rate at which food leaves the stomach, making you feel full for longer.
• •It also signals fullness to the brain, reducing appetite and cravings.

This is a critical public health and policy challenge.

• •Increasing Accessibility: The influx of cheaper generics is vital for making Semaglutide affordable and available to a larger population suffering from Type 2 diabetes and obesity, which are growing health burdens in India. This aligns with the goal of universal healthcare access.
• •Preventing Misuse: However, Semaglutide is a prescription-only drug with potential side effects. Unmonitored use for purely cosmetic weight loss, without medical supervision, could lead to adverse health outcomes. The government must ensure its 'prescription-only' status is strictly enforced.
• •Balancing Act: The government should strengthen CDSCO's regulatory oversight, particularly for the quality and safety of generic versions. Simultaneously, public awareness campaigns should educate citizens about the drug's proper use, potential risks, and the importance of medical consultation, rather than relying on celebrity endorsements or social media trends. Robust pharmacovigilance (monitoring drug safety post-market) will also be crucial.

The sale, promotion, and regulation of Semaglutide in India are primarily governed by the Drugs and Cosmetics Act, 1940, and its associated rules. The apex regulatory body responsible for its enforcement is the Central Drugs Standard Control Organisation (CDSCO). Recently, in March 2026, CDSCO issued a public advisory mandating that Semaglutide and other GLP-1 agonist drugs must be sold only on the prescription of a registered medical practitioner. Furthermore, it explicitly prohibited all manufacturers, importers, and market authorization holders from engaging in any promotional activities, including 'disease awareness campaigns' or 'influencer engagement,' that create brand recall or product visibility for prescription-only drugs.